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Liposomal amphotericin B (LAmB) is used for various fungal infections,
but it is unclear which dosing weight to use in obese patients. The purpose of this
study was to compare clinical outcomes of adjusted body weight (adjBW) versus
total body weight (TBW) dosing of LAmB. This single-center, retrospective cohort
study included patients who received LAmB for deﬁnitive therapy and whose TBW
exceeded 120% of their ideal body weight (IBW). Analyses were conducted for 3 mg/
kg for adjBW versus TBW and 5 mg/kg for adjBW versus TBW. A total of 238 patients
were included. For the 68 patients who received LAmB at 3 mg/kg, there were no
differences in safety or efﬁcacy outcomes. For the 170 patients who received LAmB
at 5 mg/kg, signiﬁcantly more patients in the TBW group experienced the primary
outcome of nephrotoxicity (57% versus 35% [P value of 0.016]) and had signiﬁcantly
higher rates of early discontinuation of LAmB due to toxicity (33% versus 17%
[P = 0.030]). There was a trend toward increased 90-day mortality in the adjBW group
(60% versus 45% [P = 0.079]); however, adjBW dosing was not associated with
increased mortality in an adjusted model. Given the lower rates of nephrotoxicity
but a possible trend toward increased mortality in patients whose TBW exceeds
120% of their IBW, dosing LAmB by adjBW may be reasonable in patients who are
not critically ill and who have lower-risk infections. In critically ill patients or those
with fungal pathogens or sites of infection associated with higher mortality risk, dosing by TBW can be considered.
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L

iposomal amphotericin B (LAmB) is an antifungal agent with activity against a wide
variety of fungi, including endemic fungi, yeasts, and molds. The typical dose is 3 to
6 mg/kg of body weight once daily depending on the infection, but whether dosing
should be based on total body weight (TBW) or adjusted body weight (adjBW) in obese
patients is uncertain. The volume of distribution of LAmB is low, at 0.1 to 0.16 liters/kg
(1), indicating a lack of extensive distribution to the fat. This ﬁnding suggests that
adjBW dosing may be sufﬁcient in obese patients.
Animal studies (2–4) have shown signiﬁcant increases in amphotericin B serum concentrations in obese rats and rabbits, with increased rates of nephrotoxicity. These data
suggest that ideal body weight (IBW) or adjBW dosing may be appropriate. In one human
pharmacokinetic study of 16 obese patients given LAmB, the authors recommended,
based on Monte Carlo simulations, a dose cap of 100 kg (e.g., 300 mg for 3-mg/kg dosing
and 500 mg for 5-mg/kg dosing) (5). Taken together, these limited previous studies suggest that dosing by adjBW in obese patients may help minimize toxicity while having similar efﬁcacy outcomes. However, to our knowledge, there have been no studies to date
comparing clinical outcomes in patients receiving adjBW versus TBW dosing of LAmB for
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FIG 1 Study population. q24h, every 24 h.

RESULTS
A total of 808 patients with orders for LAmB between 1 June 2008 and 31
November 2019 for deﬁnitive therapy were screened. From this list, 238 patients were
ultimately included, with the most common exclusions occurring as a result of the
TBW not exceeding 120% of the IBW or receipt of LAmB doses other than 3 or 5 mg/kg
(Fig. 1).
Baseline characteristics are shown in Table 1. Patients had a median age of 57 years
and were primarily Caucasian. The median weight was 93 kg, and the median body
mass index (BMI) was 31 kg/m2. The majority of patients were immunosuppressed,
most commonly because of cancer on chemotherapy or receipt of immunosuppressants. Most patients received an infectious disease consult, and 42% were admitted to
the intensive care unit (ICU). The most common infections were invasive candidiasis,
cryptococcosis, histoplasmosis, and aspergillosis, with central nervous system (CNS)
infections comprising 14% of all infections. In the 3-mg/kg comparator groups, more
patients dosed by TBW were immunosuppressed, while patients in the adjBW group
had higher Charlson comorbidity indexes; the 3-mg/kg groups were otherwise similar.
In the 5-mg/kg comparator groups, patients dosed by adjBW had higher median
weights and BMIs as well as higher Charlson comorbidity indexes but fewer Candida
infections than patients dosed by TBW. The 5-mg/kg groups were otherwise similar.
The median inpatient duration of LAmB was 6 days, with 22% of patients discharged
from the hospital on LAmB (Table 2).
Outcomes for the 3-mg/kg and 5-mg/kg analyses are shown in Table 3. For the
3-mg/kg analysis, 28% of the TBW group experienced nephrotoxicity, compared to
33% of the adjBW group. The difference was not statistically signiﬁcant, with a P value
of 0.71. There were also no signiﬁcant between-group differences for any of the secondary outcomes (Table 3 and Fig. 2).
For the 5-mg/kg analysis (Table 3), TBW dosing was associated with signiﬁcantly
more nephrotoxicity than adjBW dosing: 57% versus 35% (P value of 0.016). In the
adjBW group, the majority of nephrotoxicity cases were mild, whereas for TBW dosing,
there was a numerically higher proportion of moderate and severe nephrotoxicity
cases than in the adjBW group, although these differences did not achieve statistical
signiﬁcance. The Kaplan-Meier curve for the probability of nephrotoxicity showed an
increased risk for the TBW group at every time point, with a greater increase in risk as
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invasive fungal infections. Therefore, the purpose of this study was to compare safety and
efﬁcacy outcomes in obese patients receiving LAmB dosed by adjBW versus TBW.
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TABLE 1 Baseline patient and disease characteristics by treatment groupa
Value for group
5 mg/kg

Characteristic
Median age (yrs) (IQR)
No. (%) of male patients

All
57 (47–64)
123 (51.7)

TBW (57
patients)
56 (49–66)
28 (49.1)

adjBW (11
patients)
55 (47–60)
7 (63.6)

TBW (116
patients)
59 (48–64)
62 (53.4)

adjBW (54
patients)
56 (44–64)
26 (48.1)

No. (%) of patients of race
White
Black
Asian
Unknown

184 (77.3)
35 (14.7)
3 (1.3)
16 (6.7)

44 (77.2)
9 (15.8)
0
4 (7)

7 (63.6)
2 (18.2)
0
2 (18.2)

93 (80.2)
14 (12.1)
2 (1.7)
7 (6)

40 (74.1)
10 (18.5)
2 (1.9)
3 (5.6)

Median wt (kg) (IQR)

93 (81–104)

95 (80–103)

93 (88–108)

0.532

90 (80–102)

98 (81–108)

0.028

Median BMI (kg/m ) (IQR)

31 (29–35)

31 (29–35)

32 (28–36)

0.980

31 (29–34)

32 (30–37)

0.080

No. (%) of immunosuppressed
patients
Cancer on chemotherapy
Immunosuppressant
HIV
High-dose steroid
SOT

139 (58.4)

38 (64.9)

3 (27.3)

0.020

64 (55.2)

34 (63)

0.339

85 (35.7)
64 (26.9)
12 (5)
10 (4.2)
20 (8.4)

19 (33.3)
24 (42.1)
1 (1.8)
1 (1.8)
9 (15.8)

1 (9.1)
3 (27.3)
0
0
1 (9.1)

0.155
0.506
1.000
1.000
1.000

42 (36.2)
25 (21.6)
7 (6)
6 (5.2)
6 (5.2)

23 (42.6)
12 (22.2)
4 (7.4)
3 (5.6)
4 (7.4)

0.425
0.921
0.745
1.000
0.727

102 (42.9)
46 (19.3)
35 (14.7)
20 (8.4)

20 (35.1)
7 (12.3)
6 (10.5)
2 (3.5)

4 (36.5)
3 (27.3)
3 (27.3)
2 (18.2)

1.000
0.347
0.154
0.120

51 (44)
22 (19)
16 (13.8)
12 (10.3)

27 (50)
14 (25.9)
10 (18.5)
4 (7.4)

0.462
0.301
0.494
0.779

Median Charlson comorbidity
index (IQR)

4 (2–5)

3 (1–5)

5 (3–6)

0.031

4 (2–5)

5 (3–7)

0.042

No. of patients with ID consult/
total no. of patients (%)b

193/214 (90.2)

50/54 (92.6)

7/9 (77.8)

0.201

94/103 (91.3)

42/48 (87.5)

0.472

No. (%) of patients with
pathogen isolatedc
Candida spp.
Cryptococcus
Histoplasma
Aspergillus spp.
Zygomycetes
Coccidioides
Fusarium
Blastomyces
Other
Unknown organism

67 (28.2)
47 (19.7)
41 (17.2)
32 (13.4)
20 (8.4)
6 (2.5)
15 (6.3)
15 (6.3)
7 (2.9)
8 (3.4)

19 (33.3)
13 (22.8)
17 (29.8)
4 (7)
1 (1.8)
2 (3.5)
2 (3.5)
2 (3.5)
1 (1.8)
0

3 (27.3)
1 (9.1)
2 (18.2)
0
1 (9.1)
1 (9.1)
1 (9.1)
1 (9.1)
1 (9.1)
0

1.000
0.437
0.715
1.000
0.299
0.416
0.416
0.416
0.299

25 (21.6)
18 (15.5)
19 (16.4)
20 (17.2)
14 (12.1)
3 (2.6)
9 (7.8)
10 (8.6)
4 (3.4)
6 (5.2)

20 (37)
15 (27.8)
3 (5.6)
8 (14.8)
4 (7.4)
0
3 (5.6)
2 (3.7)
1 (1.9)
2 (3.7)

0.041
0.060
0.053
0.825
0.432
0.552
0.754
0.343
1.000
1.000

No. (%) of patients with site of
infectionc
CNS infection
Pulmonary
Other site

33 (13.9)
96 (40.3)
142 (59.7)

5 (8.8)
21 (40.1)
35 (61.4)

1 (9.1)
2 (18.2)
8 (72.7)

1.00
0.194
0.734

16 (13.5)
47 (40.5)
70 (60.3)

11 (20.4)
24 (44.4)
29 (53.7)

0.367
0.629
0.414

No. (%) of patients with ICU
admission

99 (41.6)

19 (33.3)

4 (36.4)

1.00

49 (42.2)

27 (50)

0.344

Median initial SCr (mg/dl) (IQR)

0.83 (0.65–1.07)

0.87 (0.73–1.15)

1.0 (0.61–1.21)

0.952

0.80 (0.57–1.00)

0.90 (0.66–1.19)

0.100

2

No. (%) of patients with other
comorbidities
Malignancy
CKD
BMT
Cirrhosis

P value
0.708
0.514

P value
0.366
0.520

0.458

0.734

aAbbreviations:

adjBW, adjusted body weight; BMI, body mass index; BMT, bone marrow transplant; CKD, chronic kidney disease; CNS, central nervous system; HIV, human
immunodeﬁciency virus; ICU, intensive care unit; ID, infectious diseases; IQR, interquartile range; SOT, solid-organ transplant; TBW, total body weight.
bMissing data for 21 (9.8%) patients.
cSome patients had .1 pathogen and/or .1 site of infection.
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TABLE 2 Characteristics of liposomal amphotericin B and concurrent medicationsa
Value for group
3 mg/kg
Characteristic
Median inpatient duration (days) (IQR)
No. (%) of patients discharged on
amphotericin
Median saline bolus (ml/day) (IQR)
No. (%) of patients with concurrent
medications
Other antifungal
Other nephrotoxin
Other HypoK inducers
Other HypoMg inducers

All
6 (3–14)
52 (21.8)

TBW (57
patients)
4 (2–7)
15 (26.3)

adjBW (11
patients)
5 (4–14)
3 (27.3)

P value
0.182
1.000

TBW (116
patients)
7 (3–15)
28 (24.1)

adjBW (54
patients)
8 (3–14)
6 (11.1)

P value
0.718
0.048

625 (82–1,000)

733 (0–1,000)

225 (0–1,000)

0.401

636 (216–1,000)

500 (19–1,000)

0.420

99 (41.6)
115 (48.3)
80 (33.6)
80 (33.6)

18 (31.6)
29 (50.9)
16 (28.1)
25 (43.9)

3 (27.3)
5 (45.5)
3 (27.3)
5 (45.5)

1.000
1.000
1.000
1.000

53 (45.7)
51 (44)
39 (33.6)
46 (39.7)

25 (43.3)
30 (55.6)
22 (40.7)
24 (44.4)

0.941
0.159
0.368
0.555

adjBW, adjusted body weight; HypoK, hypokalemia; HypoMg, hypomagnesemia; TBW, total body weight.

the LAmB duration increased; however, this was not statistically signiﬁcant (Fig. 3).
There were no differences in incidences of hypokalemia, hypomagnesemia, or time to
hypokalemia or hypomagnesemia (Kaplan-Meier curves not shown). There was, however, a signiﬁcantly higher early-discontinuation rate due to LAmB toxicity in the TBW
group: 33% versus 17% (P = 0.03). For the efﬁcacy outcomes, there were no signiﬁcant
differences between adjBW dosing and TBW dosing for any of the mortality, time-tomortality (Fig. 4), readmission, or length-of-stay outcomes. Although not a statistically
signiﬁcant difference, there was a trend toward increased mortality on the KaplanMeier curve and increased 90-day mortality in the adjBW group.
In the competing-risk analysis for nephrotoxicity in the 5-mg/kg groups (Table 4),
after adjusting for confounders, dosing according to TBW was found to signiﬁcantly
increase the risk for nephrotoxicity, with a hazard ratio of 1.65 (95% conﬁdence interval
[CI], 1.10 to 2.48) (P value of 0.015). Other signiﬁcant associations included a lower risk
of nephrotoxicity in patients with Candida infections and in non-ICU patients and a
higher risk of nephrotoxicity in those receiving a concomitant aminoglycoside.
A Cox regression analysis was conducted for mortality in the 5-mg/kg comparisons
to conﬁrm whether trends toward increased mortality persisted in this analysis. The
results are shown in Table 5. Dosing by adjBW was not signiﬁcantly associated with
increased mortality (hazards ratio, 1.09 [95% CI, 0.61 to 1.94]) (P value of 0.779).
Variables that were associated with increased mortality risk include increased BMI, cirrhosis, bone marrow transplant status, pulmonary infection, and ICU admission.
DISCUSSION
In this retrospective cohort analysis, for LAmB dosed at 5 mg/kg, dosing by adjBW
was found to be safer, with less nephrotoxicity and lower rates of medication discontinuation for toxicity, than dosing by TBW. The lower rates of nephrotoxicity with
adjBW dosing persisted in the competing-risk analysis. Dosing by adjBW was also not
signiﬁcantly different in efﬁcacy compared to TBW dosing in the 5-mg/kg analyses.
There was, however, a trend toward increased 90-day mortality and increased mortality
in the Kaplan-Meier analysis in the adjBW group. A Cox regression analysis was therefore conducted on the 5-mg/kg groups and found no increased association with mortality based on dosing weight, but the possibility remains that the trend toward
increased mortality with adjBW dosing reﬂects a real risk that we were underpowered
to detect. For LAmB dosed at 3 mg/kg, there were no differences in any safety or efﬁcacy outcomes between adjBW and TBW dosing. This ﬁnding may be due to smaller
sample sizes and the resultant lack of power. Overall, the study results suggest that
dosing LAmB by adjBW may be reasonable in patients who are not critically ill and
who have lower-risk infections. Given the trend toward increased mortality with adjBW
September 2021 Volume 65 Issue 9 e02366-20
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TABLE 3 Outcomes by treatment groupa
Value for group
3 mg/kg
Outcome
No. (%) of patients with nephrotoxicity
Mild
Moderate
Severe
No. (%) of patients with hypokalemia
Median potassium nadir (mmol/liter) (IQR)
No. (%) of patients with
hypomagnesemia
Median magnesium nadir (mg/dl) (IQR)b
No. (%) of patients with composite
safety data
No. (%) of patients with dose/frequency
reduction for toxicity
No. (%) of patients with early
discontinuation for toxicity
60-day mortality rate [no. (%) of
patients]
90-day mortality rate [no. (%) of
patients]
In-hospital all-cause mortality rate [no.
(%) of patients]
In-hospital fungal-infection-associated
mortality rate [no. (%) of patients]
No. (%) of patients with readmission
within 60 days
No. (%) of patients with readmission
within 90 days
Median length of stay (days) (IQR)

5 mg/kg

%
missing

TBW (57
patients)
15/53 (28.3)
5/15 (33.3)
5/15 (33.3)
5/15 (33.3)

adjBW (11
patients)
3/9 (33.3)
1/3 (33.3)
1/3 (33.3)
1/3 (33.3)

P value
0.71
1.00
1.00
1.00

TBW (116
patients)
58/102 (56.9)
19/58 (32.8)
25/58 (43.1)
14/58 (24.1)

adjBW (54
patients)
15/43 (34.9)
8/15 (53.3)
5/15 (33.3)
2/15 (13.3)

P value
0.016
0.229
0.567
0.497

0.8
1.7

16 (28.1)
2.9 (2.6–3.1)
1/55 (1.8)

4 (3.2)
2.8 (2.6–3.0)
1/11 (9.1)

0.719
0.536
0.308

70/114 (61.4)
2.9 (2.7–3.0)
18/114 (15.8)

36/54 (66.7)
3 (2.7–3.2)
4/54 (7.4)

0.51
1.0
0.15

0.8

25 (43.9)

7 (63.6)

0.325

1.2 (1–1.3)
89/114 (77.4)

1.2 (0.9–1.3)
39/54 (72.2)

0.859
0.465

4.2

3/54 (5.6)

1/10 (10)

0.50

8/110 (7.3)

3/54 (5.6)

1.00

8.9

13/52 (25)

1/10 (10)

0.43

36/110 (32.7)

9/54 (16.7)

0.030

4.6

23/53 (43.4)

4/11 (36.4)

0.748

49/112 (43.8)

27/51 (52.9)

0.275

5.5

24/53 (45.3)

5/11 (45.5)

1.00

50/111 (45)

30/50 (60)

0.079

22 (38.6)

4 (36.4)

1.00

42 (36.2)

26 (48.1)

0.14

10 (17.5)

3 (27.3)

0.428

19/115 (16.5)

10/54 (18.5)

0.748

11/35 (31.4)

4/7 (57.1)

0.20

29/74 (39.2)

14/28 (50)

0.37

11/35 (31.4)

4/7 (57.1)

0.20

32/74 (43.2)

15/28 (53.6)

0.38

12 (7–31)

18 (11–54)

0.109

25 (12–43)

31 (16–49)

0.077

0.4

adjBW, adjusted body weight; TBW, total body weight.
bMagnesium nadir data are not presented for the 3-mg/kg analyses as there was only one patient in each group with hypomagnesemia, and there were therefore no
median (IQR) data for magnesium nadirs.

dosing, in critically ill patients or those with fungal pathogens or sites of infection that
are associated with higher mortality risk, dosing by TBW can be considered.
To our knowledge, this is the ﬁrst study comparing clinical outcomes in patients
dosed by adjBW versus TBW for LAmB. Previous studies were either animal studies or
human pharmacokinetic studies. In a study by Vadiei et al. (2), obese rats given amphotericin B deoxycholate were found to have high areas under the curve (AUCs) and resultant increases in serum creatinine (SCr) from the baseline compared to normalweight rats. Similarly, in a rabbit study by Koldin et al. (3), hypercholesteremic rabbits
given amphotericin B lipid complex were also found to have higher AUCs and
increased SCr from the baseline. In another rabbit model, however, hypercholesteremic
rabbits given amphotericin B deoxycholate had no differences in SCr elevations or
mortality compared to rabbits with normal cholesterol (4). Collectively, these studies
suggest that obese animals given the same weight-based doses as nonobese animals
have signiﬁcantly increased amphotericin B exposures with associated increased toxicities and that dosing by adjBW may therefore be preferred. However, overall results
were mixed; in several of the studies, animals were hypercholesteremic rather than
obese, and there are limitations to the ability to extrapolate animal data to humans.
There has been one pharmacokinetic study of LAmB in obese patients, in which
Monte Carlo simulations were done on 16 morbidly obese patients given LAmB dosed
by TBW (5). Based on their models, those authors recommended a dose cap at 100 kg
of body weight (e.g., 300 mg for 3-mg/kg dosing and 500 mg for 5-mg/kg dosing).
September 2021 Volume 65 Issue 9 e02366-20
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These results similarly suggest that for obese patients, TBW dosing may not be the
optimal strategy. This study was small, however, and did not assess clinical outcomes.
Consistent with the results of these previous studies, our study found that dosing
by TBW in obese patients was associated with signiﬁcantly higher rates of nephrotoxicity, with this association also being seen after adjusting for confounders in the competing-risk multivariate analysis. Rates of nephrotoxicity were relatively high in our study,
occurring in 44% of patients overall. In previous studies of LAmB dosed from 3 to
6 mg/kg daily (6–8), rates of nephrotoxicity from LAmB ranged from 18.7% to 47%,
depending on the indication and dosage. The incidence in our study is consistent with
the ones in these previous studies but falls within the higher end of the range, possibly
due to a sicker patient population or the inclusion of obese patients only and therefore
higher absolute doses.
The consideration of a lower incidence of nephrotoxicity development with adjBW
dosing should be balanced with the trend toward increased mortality risk seen in our
study. The numbers were overall small, and it is possible that we were simply underpowered to detect a statistically signiﬁcant difference in mortality. Our study population was also highly heterogeneous in terms of illness severity and fungal pathogen;
the possibility of increased mortality risk is of particular concern in critically ill patients
and those with higher-mortality-risk infections such as mucormycoses. In a previous
trial of LAmB in patients with cryptococcal meningitis (6), LAmB dosed at 3 mg/kg daily
was associated with rates of 10-week mortality similar to those of LAmB at 6 mg/kg
daily (13.9% versus 9.5%); although statistical analyses between these two groups
were not conducted, the authors of that study concluded that 3 mg/kg daily may be
sufﬁcient for cryptococcal meningitis. The mortality rates in this previous study, however, were much lower than the 48% overall 90-day mortality risk seen in our study.
Dosing differences likely matter more when mortality risk is higher. In another study of
44 immunocompromised patients with Aspergillus, Fusarium, and Zygomycetes infections, patients received either 7.5 mg/kg, 10 mg/kg, 12.5 mg/kg, or 15 mg/kg of LAmB
daily (9). The groups were too small to conduct statistical analyses on safety outcomes
September 2021 Volume 65 Issue 9 e02366-20
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FIG 2 Kaplan-Meier survival curve for 3 mg/kg LAmB.
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between groups. Overall, 50% of patients experienced nephrotoxicity, but no patients
required renal replacement therapy, and there was no dose-limiting nephrotoxicity in
any of the dosing groups. While nephrotoxicity risk is an important consideration
when choosing LAmB doses, when the mortality risk is very high, the balance of risk
versus beneﬁt may favor more aggressive dosing strategies. Therefore, dosing LAmB
by adjBW may be reasonable in patients who are not critically ill and who have lowerrisk infections. In critically ill patients or those with fungal pathogens or sites of infection that are associated with higher mortality risk, dosing by TBW can be considered.
Adding to the currently available literature, our study was the ﬁrst to examine clinical
outcomes of different dosing weights in a relatively large cohort of patients. Our study
population also included a substantial portion of critically ill and immunocompromised
patients, increasing the applicability of the results to these patient populations.
Our study did, however, have several limitations. First, this was a single-center retrospective study with the inherent associated limitations and possible confounders. There
were several between-group differences in baseline characteristics that may have
affected outcomes. Although our heterogeneous patient population increased study
applicability, the inclusion of many different fungal pathogens and patient populations
may also have increased the risk of confounding. To account for these limitations, we
conducted a competing-risk multivariate analysis for nephrotoxicity and a multivariate
analysis for mortality, which conﬁrmed the results seen in the primary analyses. In addition, we found differences in safety outcomes for the 5-mg/kg analyses but not for the
3-mg/kg analyses, likely due to the very small size and, therefore, the lack of power in
the 3-mg/kg groups. Finally, laboratory values to analyze rates of nephrotoxicity, hypomagnesemia, and hypokalemia were assessed only for the inpatient duration of LAmB
due to limited access to retrospective outpatient data. It is possible that the development of nephrotoxicity, hypomagnesemia, or hypokalemia may have been missed in
patients who developed these outcomes as outpatients. However, a minority of patients,
22%, were discharged on LAmB. In addition, we most likely missed only minor cases of
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FIG 3 Nephrotoxicity Kaplan-Meier curve for 5 mg/kg LAmB.
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outpatient LAmB adverse events. If any of these toxicities were severe enough to warrant
readmission, unless this readmission occurred at a facility outside the health system, this
toxicity would have then been captured and counted. A ﬁnal consideration is the TBW of
patients in our study: the median TBW was 93 kg, with a maximum weight of 160 kg.
Dosing beyond this weight was not able to be assessed in our study; additional studies
may be warranted to determine appropriate dosing strategies in patients beyond this
body weight.
In conclusion, dosing liposomal amphotericin B by adjBW was associated with less
nephrotoxicity but also a trend toward increased mortality compared to dosing by
TBW in obese patients. Based on our ﬁndings, for patients whose TBW exceeds 120%
of their IBW, dosing LAmB by adjBW may be reasonable in patients who are not critically ill and who have lower-risk infections. In critically ill patients or those with fungal
pathogens or sites of infection that are associated with higher mortality risk, dosing by
TBW can be considered.
MATERIALS AND METHODS
This was a single-center, retrospective, observational cohort study conducted at Barnes-Jewish
Hospital in St. Louis, MO. The study was approved by the Washington University Institutional Review
Board.
All adult patients who had orders for LAmB between 1 June 2008 and 30 November 2019 for deﬁnitive therapy were screened. Deﬁnitive therapy was deﬁned as treatment for a fungal infection conﬁrmed
by positive microbiology, including the following: positive fungal cultures except for Candida species in
respiratory or urinary specimens; positive Histoplasma or Cryptococcus antigen; or positive Coccidioides,
Histoplasma, or Blastomyces antibodies. Patients with ICD-9 or ICD-10 codes for invasive fungal infection
were also included to capture patients who had positive fungal microbiology in the outpatient setting
or at outside hospitals prior to transfer.
Patients were included if their TBW exceeded 120% of their IBW and if they were treated with either
3 mg/kg or 5 mg/kg of LAmB every 24 h dosed based on either adjBW or TBW. Patients were excluded if
there was no recorded height available in the patient chart, if the LAmB frequency was greater than every 24 h, if LAmB was ordered but never given, or if there was no positive fungal microbiology. Patients
who were on renal replacement therapy at the start of LAmB were excluded from the nephrotoxicity
analysis.
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FIG 4 Kaplan-Meier survival curve for 5 mg/kg LAmB.
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TABLE 4 Nephrotoxicity competing-risk analysis for the 5-mg/kg dosea
Variable
Dosing wt: TBW vs adjBW
Candida infection
Admitting unit: non-ICU
Aminoglycoside

95% CI
1.10–2.48
0.32–0.95
0.42–0.95
1.16–3.94

P value
0.015
0.033
0.027
0.015

adjBW, adjusted body weight; ICU, intensive care unit; TBW, total body weight.

For the time period included in the analysis, LAmB dosing weight was left up to the provider’s discretion,
with no standardized internal guidance on which dosing weight to choose. Separate analyses were performed comparing 3-mg/kg adjBW versus TBW and 5-mg/kg adjBW versus TBW groups. Doses of between
2.5 and 3.5 mg/kg were counted as 3 mg/kg, while doses of between 4.5 and 5.5 mg/kg were counted as
5 mg/kg. Calculations were made for both adjBW and TBW, and all doses that did not fall within these parameters were excluded. The patient weight used for all calculations was the weight nearest LAmB initiation.
The daily dose administered for the majority of the LAmB duration was used in the analyses.
Study deﬁnitions. Patients were considered immunosuppressed if they had any of the following:
HIV with CD4 counts of less than 200 cells/mm3, cancer on chemotherapy with resultant neutropenia,
history of solid-organ transplant, receipt of immunosuppressants within the last 30 days, or receipt of
methylprednisolone at 1 mg/kg daily or the equivalent dose of another steroid.
ICU admission was deﬁned as a patient being located in the ICU at the time of the ﬁrst LAmB order.
Time-to-toxicity and time-to-mortality outcomes were assessed with the day of the initial LAmB order as
day 1. When examining 60- and 90-day readmission data, readmissions to any hospital within the health
system were captured.
Nephrotoxicity was deﬁned as an increase in serum creatinine (SCr) to $1.5 the baseline and was
further categorized as mild nephrotoxicity if SCr was elevated to $1.5 the baseline but ,2 the baseline, moderate nephrotoxicity if SCr was elevated to $2 the baseline but ,3 the baseline, or severe
nephrotoxicity if SCr was elevated to $3 the baseline or if renal replacement therapy was initiated.
Hypokalemia was deﬁned as a potassium level of ,3.3 mmol/liter at any point during inpatient LAmB
treatment, while hypomagnesemia was deﬁned as a magnesium level of ,1.4 mg/dl at any time during
inpatient LAmB treatment. Potassium or magnesium nadirs were analyzed only for patients who developed hypokalemia or hypomagnesemia, respectively. Laboratory values, including SCr, potassium, and
magnesium, were assessed up until the last inpatient day of LAmB therapy for each patient.
Outcomes. The primary outcome was the incidence of nephrotoxicity. Secondary safety outcomes
included time to nephrotoxicity; time to and incidence of hypokalemia; time to and incidence of hypomagnesemia; magnesium and potassium nadirs; the composite safety outcome of nephrotoxicity, hypokalemia, or hypomagnesemia; dose or frequency reduction for toxicity; or early discontinuation for toxicity. Efﬁcacy outcomes included all-cause 60- and 90-day mortality, all-cause and fungal-infection-related
in-hospital mortality, time to mortality, readmission within 60 and 90 days, and hospital length of stay.
Statistical analyses. Fisher’s exact or chi-square tests were used for categorical data, Student’s t
tests or Mann-Whitney U tests were used for continuous data, and Kaplan-Meier analyses were used for

TABLE 5 Multivariate Cox analysis of the 5-mg/kg dosea
Characteristic
Dosing wt: adjBW vs TBW

Hazard ratio
1.09

95% CI
0.61–1.94

P value
0.779

Age (yrs)
18–40
41–60
.60

1.00
1.58
2.47

0.96–6.38
0.62–4.03

0.299
0.061

BMI
Cancer on chemotherapy
Immunocompromised
Cirrhosis
BMT
CCI
ID consult
Cryptococcus or endemic fungi
CNS infection
Pulmonary infection
ICU admission
Concomitant other antifungal
Length of stay

1.08
1.55
1.35
3.04
2.06
1.09
0.85
0.73
1.09
2.07
2.34
0.72
0.99

1.02–1.14
0.70–3.42
0.59–3.12
1.31–7.07
1.07–3.96
0.98–1.20
0.39–1.86
0.36–1.49
0.43–2.78
1.18–3.64
1.26–4.31
0.39–1.33
0.99–1.00

0.007
0.281
0.479
0.010
0.030
0.122
0.691
0.388
0.852
0.012
0.007
0.298
0.306

aAbbreviations:

adjBW, adjusted body weight; BMI, body mass index; BMT, bone marrow transplant; CCI,
Charlson comorbidity index; CNS, central nervous system; ICU, intensive care unit; ID, infectious diseases; TBW,
total body weight [ x 2(16) = 55 (P , 0.001)].
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Hazard ratio
1.65
0.55
0.63
2.13
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time-to-event data, as appropriate. A 2-sided P value of ,0.05 was considered statistically signiﬁcant for
all tests.
A Cox competing-risk model was used to estimate the risk of nephrotoxicity. In-hospital mortality
was considered a competing risk. A multivariate Cox proportional-hazards model was also conducted
for the secondary outcome of mortality. Univariate analyses were conducted on variables in Tables 1
and 2. With the exception of age, continuous covariates such as LAmB dose and initial creatinine clearance (CrCl) were included in the models as linear variables. Covariates with a P value of ,0.15 on univariate analysis were retained in the ﬁnal multivariate model; all covariates were assessed for collinearity. Goodness of ﬁt was assessed using the Omnibus test of model coefﬁcients for the Cox regression
analysis.
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